|
We asked 50 pharma leaders, has your department been downsized? If so, by how much?
| Up to 10% |
43% |
10-25% |
36% |
| 25-50% |
7% |
| More than 50% |
14% |
 |
|
|
|
|
|
|
|
7 May, 2013
|
|
European Biotech Struggles to Thrive
Several European governments have been attempting to boost the biotech sector through measures such as tax incentives. But external funding from investors and deals with larger companies are necessary for growth within biotech companies, and in this respect Europe is struggling when compared with the US ...Read more |
US Manufacturers under Pressure to Manage Painkillers
Limiting opioid abuse is the most crucial public health issue for the Center for Drug Evaluation and Research (CDER). But the challenge is to assure patient access to these crucial drugs while reducing the “epidemic of abuse and misuse” ... Read more |
PhRMA Dismayed by IP Report
Pharmaceutical Research and Manufacturers of America (PhRMA) International Vice-President Jay Taylor has expressed concerns over the Office of the United States Trade Representative’s (USTR) 2013 Special 301 Report on the state of intellectual property (IP) rights protection and enforcement in trading partners around the world and reflects the US Administration’s resolve to maintain IP protection worldwide... Read more
|
Tough Times Ahead for New Drugs Under NHS England?
Last month NHS England (formerly the NHS Commissioning Board) set out 15 commissioning policies in 250 pages. They’re important, as they set out the approach NHS England will take when they’re spending some £20 billion plus worth of services... Read more
|
|
|
|
